Travere Therapeutics (TVTX) Reports Q2 Loss, Tops Revenue Estimates

Travere Therapeutics (TVTX) came out with a quarterly loss of $0.90 per share versus the Zacks Consensus Estimate of a loss of$ 0.87. This compares to loss of $1.13 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -3.45%. A quarter ago, it was expected that this drug developer would post a loss of$ 0.98 per share when it actually produced a loss of $1.76, delivering a surprise of -79.59%. Over the last four quarters, the compa ...